Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2

Status

Recruiting 9Not yet recruiting 5Completed 3Active not recruiting 3

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Rectal Cancer Patients 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 65Magnetic Resonance Spectroscopy 44Cyclophosphamide 32Carboplatin 31Gemcitabine 30Biopsy 28Cisplatin 25Bevacizumab 25Radiotherapy 24pembrolizumab 23Paclitaxel 23Standard of Care 22Oxaliplatin 22fludarabine 21Nivolumab 21Drug Therapy 21Capecitabine 21venetoclax 20Interviews as Topic 18Injections 17Radiosurgery 16Blood Specimen Collection 16toripalimab 15cemiplimab 15Dexamethasone 15Azacitidine 15tislelizumab 14Irinotecan 14Docetaxel 14anlotinib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × camrelizumab × 90 days × Clear all
NCT07618546 2026-06-01

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Henan Cancer Hospital

Phase NA Not yet recruiting
208 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07555860 2026-04-29

Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
28 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07521605 2026-04-13

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
44 enrolled
Gastrointestinal

Rectal Cancer Patients

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07466901 2026-03-12

A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

Fudan University

Phase NA Not yet recruiting
30 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡